Navigation Links
Anthera Pharmaceuticals to Present at Deutsche Bank Securities' 35th Annual Health Care Conference
Date:4/26/2010

HAYWARD, Calif., April 26 /PRNewswire-FirstCall/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced Paul F. Truex, Anthera's President and Chief Executive Officer will present at the Deutsche Bank 35th Annual Health Care Conference in Boston, MA on Monday, May 3, 2010 at approximately 9:20 am Eastern Time.  

To access live audio broadcasts of these presentations, or the subsequent archived recordings, log onto http://www.anthera.com.  Please connect to the website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.  

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLyS, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.

CONTACT: Juliane Snowden of Burns McClellan, Inc., jsnowden@burnsmc.com or 212.213.0006.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
2. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
3. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
5. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
8. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
9. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
11. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Sept. 1, 2017  Bayer will present the latest research ... for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... new preclinical and clinical data on Bayer,s marketed portfolio and ... projects. "We value ... in cancer research at ESMO," said Carsten Brunn , ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
(Date:8/28/2017)... , Aug. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... on Monday, September 11, 2017, in New York ... executive officer, is scheduled to present at 11:05 a.m. Eastern ... accessed at http://ir.hill-rom.com/events.cfm . A recorded replay will be ... through December 10, 2017. ...
Breaking Medicine Technology:
(Date:9/21/2017)... Renton, WA (PRWEB) , ... September 21, 2017 ... ... inspection technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 ... need of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction treatment ... a time when Virginia faces an opioid epidemic. , Last year, ... of 38 percent from 2015, underscoring the need for additional addiction treatment options. ...
(Date:9/21/2017)... ... September 21, 2017 , ... In the inaugural 30-minute podcast ... Professor of Education Gregory A. Smith examines student privacy issues with University of ... Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . , Join Smith ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror ... fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September ... refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting ...
Breaking Medicine News(10 mins):